Kestra Medical Technologies Ltd. ( (KMTS) ) has released its Q4 earnings. Here is a breakdown of the information Kestra Medical Technologies Ltd. presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Kestra Medical Technologies, Ltd. is a wearable medical device and digital healthcare company focused on improving cardiovascular disease outcomes through innovative monitoring and therapeutic intervention technologies.
In its latest earnings report, Kestra Medical Technologies announced significant financial growth for the fourth quarter and fiscal year 2025, highlighted by a substantial increase in revenue and gross margins.
For the fourth quarter of fiscal year 2025, Kestra reported a revenue of $17.2 million, marking a 71% increase from the previous year. The company also achieved a gross margin of 44.3%, a notable improvement from 13.9% in the prior year. For the entire fiscal year, revenue reached $59.8 million, a 115% increase compared to fiscal year 2024, with a gross margin of 40.5% compared to 1.3% in the previous year. These gains were driven by increased demand for the company’s ASSURE® system, improved revenue cycle management, and a higher mix of in-network patients.
Despite the positive revenue growth, Kestra reported a GAAP net loss of $51.1 million for the fourth quarter and $113.8 million for the fiscal year, primarily due to increased operating expenses related to the company’s IPO and share-based compensation. However, the adjusted EBITDA loss showed improvement, decreasing to $68.4 million from $72.0 million in the previous year.
Looking ahead, Kestra Medical Technologies has set a revenue guidance of $85 million for fiscal year 2026, representing a 42% increase from fiscal year 2025. The company remains optimistic about its growth prospects, driven by ongoing innovation and a strong focus on expanding its market presence and supporting prescribers and patients alike.